ClinicalTrials.gg
RecruitingNCT05648253Updated Apr 22, 2025

Feasibility of Hyivy Device Post-Radiation for Pelvic Malignancies

An interventional study of Hyivy Intravaginal Device in Vaginal Stenosis, Radiation Therapy and Cancer, sponsored by Hyivy Health Inc. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-22.

Primary conditionPelvic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pelvic Neoplasms
Why
  1. The study's listed conditions name Pelvic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hyivy Health Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Vaginal dilator therapy (VDT) with static dilators is often prescribed to patients following vaginal or pelvic radiation therapy. This study seeks to evaluate the feasibility of a novel intravaginal device that delivers patient-controlled dilation (Hyivy device). The study is designed as a proof-of-concept single-arm pilot study. The primary objective is to assess safety and tolerability, while also evaluating changes in health-related quality of life and pelvic pain.

Read the detailed description

Radiation therapy is a common treatment for cancer in the pelvic area and is considered a mainstay of treatment for cancers of the cervix, uterus, and anorectum. Patients with a vagina and vaginal canal who undergo vaginal or pelvic radiation therapy are at risk for developing vaginal stenosis, defined in part by a shortening and/or narrowing of the vaginal canal, which can lead to damaged tissue and pain with examination/vaginal penetration.

Vaginal dilator therapy (VDT) is prescribed to prevent vaginal stenosis. Adherence to VDT in the months following radiation is quite low. Reasons may include limited size options of static dilators, lack of time, general fatigue, emotional well-being, and associating dilator use with underlying malignancy and radiation treatment. Alternatives to static dilators that are safe and effective may improve adherence to VDT and improve patient quality of life.

02

Conditions studied

  • Vaginal Stenosis
  • Radiation Therapy
  • Cancer
  • Pelvic Pain
  • Pelvic Cancer

Browse trials for

Keywords

  • Dilator
  • Post radiation therapy
03

In context

Pelvic Neoplasms Reclassified

82 studies on the registry are indexed under Pelvic Neoplasms; 28 are open to participants now.

This study's planned enrollment of 12 is below the median of 47 across 50 interventional studies indexed under Pelvic Neoplasms.

Browse Pelvic Neoplasms studies →

Lead sponsor

Hyivy Health Inc is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Pelvic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age ≥ 18 at the time of enrollment
  • 2.Patient with a vagina or vaginal canal who have completed radiation therapy (either external beam or brachytherapy, or a combination of both) for endometrial cancer, cervical cancer, anal cancer, or rectal cancer, without concomitant chemotherapy
  • 3.Generally in good health (other than due to cancer), at the discretion of the investigator(s)
  • 4. (ECOG) score or 0 to 2
  • 5.Participants must be (natural or surgically) for at least 1 year prior to screening or be surgically sterile (absence of ovaries and/or uterus); or, a participant of must agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months.
  • 6.Agree not to use other dilators for the 12-week intervention period
  • 7.Must have the ability to charge the device
  • 8.Must be willing and able to insert intravaginal device
  • 9.Able to understand, comply and consent to protocol requirements and instructions
  • 10.Able to attend scheduled study visits and complete required investigations
  • 11.Ability to understand and willingness to sign written

Exclusion criteria

Exclusion Criteria:

  • 1.Participants who are pregnant or planning to become pregnant during the trial
  • 2.Any major surgery in the past 3 months unless post-surgery dilator use is recommended by a physician, or anticipates having a major surgery during the study
  • 3.Any other medical condition or clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of the product or that may affect the interpretation of the results or leave the patient at high risk from treatment complications, at the discretion of the investigator(s)
  • 4.Allergy to Hyivy device's materials
  • 5.Active pelvic or gynaecological infection
  • 6.Current use of antibiotics for any infection
  • 7.Have open wounds, cuts, or open sores present in the vaginal or pelvic area
  • 8.Severe atrophic vaginitis or very dry, itchy, or sore vagina/vaginal area, at the discretion of the investigator(s)
  • 9.Hypoesthesia or loss in sensation of the pelvic floor
  • 10.Total and/or partial prolapse of the uterus and/or vagina
  • 11.Symptoms of severe urinary retention, severe extra-urethral incontinence, or overflow incontinence
  • 12.Unable to position the device according to directions for use
  • 13.Use of any medical devices that may interfere with the investigational device's function, such as pacemakers, ventilators, and ear implants
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Hyivy Intravaginal Device

    Participants will receive a Hyivy intravaginal device for at-home use. Recommended use is three times per week for 12 weeks and consists of 10 minutes of heat (37-39ºC) and 10 minutes of dilation per session.

    Device: Hyivy Intravaginal Device

Interventions

  • DeviceHyivy Intravaginal Device

    Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of the Hyivy device

    Occurrence of adverse events (AE) and serious adverse events (SAE).

    Time frame: Up to 12-weeks

Secondary outcomes

  1. Quality of Life (FACT-G)

    Changes in health-related quality of life (HRQoL) as assessed by the Functional Assessment of Cancer Therapy - General (FACT-G).

    Time frame: Baseline, 6-weeks, 12-weeks

  2. Pelvic pain (VAS)

    Changes in pelvic pain as assessed by a visual analog scale (VAS).

    Time frame: Baseline, 6-weeks, 12-weeks

  3. Adherence to study protocol

    Usage data collected by the Hyivy device will be used to assess participant adherence to the study regimen of 3 times/week device use.

    Time frame: 6-weeks, 12-weeks

Other outcomes

  1. Device usability and patient satisfaction

    Study-specific questionnaire to gather patient feedback

    Time frame: 12-weeks

07

Study locations

1 of 1 sites recruiting
  • Grand River Regional Cancer Centre, Waterloo Regional Health Network @ Midtown
    Kitchener, Ontario N2G 1G3, Canada
    Recruiting
08

References and documents

Publications

  • Damast S, Jeffery DD, Son CH, Hasan Y, Carter J, Lindau ST, Jhingran A. Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology. Pract Radiat Oncol. 2019 Nov;9(6):479-491. doi: 10.1016/j.prro.2019.07.001. Epub 2019 Jul 11. PubMed 31302301 ↗
  • International Clinical Guideline Group. International Guidelines on Vaginal Dilation after Pelvic Radiotherapy.; 2012. https://owenmumford.com/us/wp-content/uploads/sites/3/2014/11/Dilator-Best-Practice-Guidelines.pdf.
  • Law E, Kelvin JF, Thom B, Riedel E, Tom A, Carter J, Alektiar KM, Goodman KA. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. Radiother Oncol. 2015 Jul;116(1):149-55. doi: 10.1016/j.radonc.2015.06.018. Epub 2015 Jul 8. PubMed 26164775 ↗
  • Bakker RM, Vermeer WM, Creutzberg CL, Mens JW, Nout RA, Ter Kuile MM. Qualitative accounts of patients' determinants of vaginal dilator use after pelvic radiotherapy. J Sex Med. 2015 Mar;12(3):764-73. doi: 10.1111/jsm.12776. Epub 2014 Nov 25. PubMed 25424559 ↗
  • Araya-Castro P, Sacomori C, Diaz-Guerrero P, Gayan P, Roman D, Sperandio FF. Vaginal Dilator and Pelvic Floor Exercises for Vaginal Stenosis, Sexual Health and Quality of Life among Cervical Cancer Patients Treated with Radiation: Clinical Report. J Sex Marital Ther. 2020;46(6):513-527. doi: 10.1080/0092623X.2020.1760981. Epub 2020 May 2. PubMed 32364016 ↗

Individual participant data

Plan to share: No — There is no plan to make individual participant data available to other researchers

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.

Of 23 interventional studies with no phase under Pelvic Neoplasms, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 13, 2022
StartActual
Apr 11, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05648253
Lead sponsor
Hyivy Health Inc
Collaborators
Grand River Hospital
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
Apr 11, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 22, 2025

Study contacts

Daniel Glick, MD
Contact
Daniel.Glick@grhosp.on.ca
(519) 749-4370 ext. 5489
Daniel Glick, MD
principal investigator · Grand River Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion